Your browser doesn't support javascript.
loading
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Tomlins, Scott A; Khazanov, Nickolay A; Bulen, Benjamin J; Hovelson, Daniel H; Shreve, Melissa J; Lamb, Laura E; Matrana, Marc R; Burkard, Mark E; Yang, Eddy Shih-Hsin; Edenfield, William Jeffery; Dees, E Claire; Onitilo, Adedayo A; Thompson, Michael; Buchschacher, Gary L; Miller, Alan M; Menter, Alexander; Parsons, Benjamin; Wassenaar, Timothy; Hwang, Leon C; Suga, J Marie; Siegel, Robert; Irvin, William; Nair, Suresh; Slim, Jennifer N; Misleh, Jamal; Khatri, Jamil; Masters, Gregory; Thomas, Sachdev; Safa, Malek; Anderson, Daniel M; Kwiatkowski, Kat; Mitchell, Khalis; Hu-Seliger, Tina; Drewery, Stephanie; Fischer, Andrew; Plouffe, Komal; Czuprenski, Eric; Hipp, Jennifer; Reeder, Travis; Vakil, Hana; Johnson, D Bryan; Rhodes, Daniel R.
Afiliación
  • Tomlins SA; Strata Oncology, Ann Arbor, MI, USA. scott.tomlins@strataoncology.com.
  • Khazanov NA; Strata Oncology, Ann Arbor, MI, USA.
  • Bulen BJ; Strata Oncology, Ann Arbor, MI, USA.
  • Hovelson DH; Strata Oncology, Ann Arbor, MI, USA.
  • Shreve MJ; Strata Oncology, Ann Arbor, MI, USA.
  • Lamb LE; Strata Oncology, Ann Arbor, MI, USA.
  • Matrana MR; Ochsner Cancer Institute, New Orleans, LA, USA.
  • Burkard ME; University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
  • Yang ES; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
  • Edenfield WJ; Prisma Health Greenville Memorial Hospital, Greenville, SC, USA.
  • Dees EC; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
  • Onitilo AA; Cancer Care and Research Center, Marshfield Clinic Research Institute, Marshfield, WI, USA.
  • Thompson M; Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, USA.
  • Buchschacher GL; Tempus Labs, Chicago, IL, USA.
  • Miller AM; Kaiser Permanente Southern California, Los Angeles, CA, USA.
  • Menter A; SCL Health-CO, Broomfield, CO, USA.
  • Parsons B; Translational Drug Development, Scottsdale, USA.
  • Wassenaar T; Kaiser Permanente Colorado, Lone Tree, CO, USA.
  • Hwang LC; Gundersen Health System, La Crosse, WI, USA.
  • Suga JM; UW Health Cancer Center at ProHealth Care, Waukesha, WI, USA.
  • Siegel R; Kaiser Permanente of the Mid-Atlantic States, Rockville, MD, USA.
  • Irvin W; Kaiser Permanente Northern California, Vallejo, CA, USA.
  • Nair S; Bon Secours St. Francis Cancer Center, Greenville, SC, USA.
  • Slim JN; Bon Secours Cancer Institute, Midlothian, VA, USA.
  • Misleh J; Lehigh Valley Topper Cancer Institute, Allentown, PA, USA.
  • Khatri J; MultiCare Regional Cancer Center, Tacoma, WA, USA.
  • Masters G; The US Oncology Network, Newark, DE, USA.
  • Thomas S; ChristianaCare Oncology Hematology, Newark, DE, USA.
  • Safa M; Medical Oncology Hematology Consultants, Helen F Graham Cancer Center and Research Institute,, Newark, DE, USA.
  • Anderson DM; Kaiser Permanente - Northern California, Oakland, CA, USA.
  • Kwiatkowski K; Kettering Health, Kettering, OH, USA.
  • Mitchell K; Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, MN, USA.
  • Hu-Seliger T; Strata Oncology, Ann Arbor, MI, USA.
  • Drewery S; Strata Oncology, Ann Arbor, MI, USA.
  • Fischer A; Strata Oncology, Ann Arbor, MI, USA.
  • Plouffe K; Strata Oncology, Ann Arbor, MI, USA.
  • Czuprenski E; Strata Oncology, Ann Arbor, MI, USA.
  • Hipp J; Strata Oncology, Ann Arbor, MI, USA.
  • Reeder T; Strata Oncology, Ann Arbor, MI, USA.
  • Vakil H; Strata Oncology, Ann Arbor, MI, USA.
  • Johnson DB; Strata Oncology, Ann Arbor, MI, USA.
  • Rhodes DR; Strata Oncology, Ann Arbor, MI, USA.
Commun Med (Lond) ; 3(1): 14, 2023 Feb 07.
Article en En | MEDLINE | ID: mdl-36750617
Therapies activating the immune system (checkpoint inhibitors) have revolutionized the treatment of patients with advanced cancer, however new molecular tests may better identify patients who could benefit. Using treatment data and clinical molecular test results, we report the development and validation of Immunotherapy Response Score (IRS) to predict checkpoint inhibitor benefit. Across patients with more than 20 advanced cancer types, IRS better predicted checkpoint inhibitor benefit than currently available tests. Data from >20,000 patients showed that IRS identifies ~8% of patients with advanced cancer who may dramatically benefit from checkpoint inhibitors but would not receive them today based on currently available tests. Our approach may help clinicians to decide which patients should receive checkpoint inhibitors to treat their disease.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Commun Med (Lond) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Commun Med (Lond) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos